{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:29:00Z","timestamp":1781234940373,"version":"3.54.1"},"reference-count":22,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54 CA163072"],"award-info":[{"award-number":["U54 CA163072"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2020,4,15]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      With the increasing use of multigene panel tests, pathogenic and likely pathogenic (P\/LP) variants are identified more frequently in the moderate\u2010penetrance breast cancer genes\n                      <jats:italic>ATM<\/jats:italic>\n                      and\n                      <jats:italic>CHEK2<\/jats:italic>\n                      . Lifetime breast cancer risk among women with P\/LP variants in these genes generally exceeds 20%, meeting the threshold at which high\u2010risk breast cancer screening through breast magnetic resonance imaging (MRI) is recommended.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Among a registry\u2010based sample of 56\n                      <jats:italic>ATM<\/jats:italic>\n                      and 69\n                      <jats:italic>CHEK2<\/jats:italic>\n                      carriers, the authors sought to determine the percentage of relatives in whom a P\/LP variant would impact breast cancer surveillance. Lifetime breast cancer risks for unaffected, female first\u2010degree and second\u2010degree relatives were estimated using the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among first\u2010degree relatives of\n                      <jats:italic>ATM<\/jats:italic>\n                      and\n                      <jats:italic>CHEK2<\/jats:italic>\n                      carriers, only 22.6% and 14.9%, respectively, were found to have lifetime breast cancer risks of \u226520% based on family cancer history alone; however, when including the proband's P\/LP variant in the model, these percentages increased significantly to 56.6% and 55.3%, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.0001 and\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.0001, respectively). Similar increases in lifetime breast cancer risks were found among second\u2010degree relatives.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The results of the current study suggest that the majority of female first\u2010degree and second\u2010degree relatives of\n                      <jats:italic>ATM<\/jats:italic>\n                      and\n                      <jats:italic>CHEK2<\/jats:italic>\n                      carriers do not qualify for breast MRI based on family cancer history alone. Therefore, testing for these genes, as well as awareness of positive moderate\u2010penetrance breast cancer gene results in the family, may impact MRI eligibility. These findings highlight the potential usefulness of and need for breast cancer risk models that incorporate moderate\u2010penetrance gene positivity to inform screening recommendations among at\u2010risk family members.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.32715","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T11:34:30Z","timestamp":1579692870000},"page":"1651-1655","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Breast cancer screening implications of risk modeling among female relatives of\n                    <i>ATM<\/i>\n                    and\n                    <i>CHEK2<\/i>\n                    carriers"],"prefix":"10.1002","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8007-8734","authenticated-orcid":false,"given":"Anne E.","family":"Weidner","sequence":"first","affiliation":[{"name":"Division of Genetic Medicine, Department of Medicine Vanderbilt University Medical Center Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariel E.","family":"Liggin","sequence":"additional","affiliation":[{"name":"Division of Genetic Medicine, Department of Medicine Vanderbilt University Medical Center Nashville Tennessee"},{"name":"Department of Biology Tennessee State University Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda I.","family":"Zuniga","sequence":"additional","affiliation":[{"name":"Division of Genetic Medicine, Department of Medicine Vanderbilt University Medical Center Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann L.","family":"Tezak","sequence":"additional","affiliation":[{"name":"Division of Genetic Medicine, Department of Medicine Vanderbilt University Medical Center Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia L.","family":"Wiesner","sequence":"additional","affiliation":[{"name":"Division of Genetic Medicine, Department of Medicine Vanderbilt University Medical Center Nashville Tennessee"},{"name":"Division of Genetic Medicine, Department of Medicine Vanderbilt\u2010Ingram Cancer Center Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuya","family":"Pal","sequence":"additional","affiliation":[{"name":"Division of Genetic Medicine, Department of Medicine Vanderbilt University Medical Center Nashville Tennessee"},{"name":"Division of Genetic Medicine, Department of Medicine Vanderbilt\u2010Ingram Cancer Center Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0424"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29010"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4754-2"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7792600"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/301673"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.21971"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng879"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.0778"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5922"},{"key":"e_1_2_9_11_1","unstructured":"American Cancer Society.American Cancer Society screening recommendations for women at high risk. Updated October 3 2019. Accessed October 30 2019.https:\/\/www.cancer.org\/cancer\/breast-cancer\/screening-tests-and-early-detection\/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html"},{"key":"e_1_2_9_12_1","unstructured":"National Comprehensive Cancer Network.National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Genetic\/familial high\u2010risk assesssment: breast and ovarian. Updated January 18 2019. Accessed June 14 2019.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf"},{"key":"e_1_2_9_13_1","unstructured":"National Comprehensive Cancer Network.National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Breast cancer screening and diagnosis. Updated May 17 2019. Accessed June 17 2019.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast-screening.pdf"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.730"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.31"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10463356.2018.1525993"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-013-0525-6"},{"key":"e_1_2_9_18_1","first-page":"260847","article-title":"Identification, evaluation, and treatment of patients with hereditary cancer risk within the United States","volume":"2013","author":"Cragun D","year":"2013","journal-title":"ISRN Oncol"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare4010006"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20415"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2919"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2690"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.90"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.32715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.32715","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:56:33Z","timestamp":1761886593000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.32715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,4,15]]}},"alternative-id":["10.1002\/cncr.32715"],"URL":"https:\/\/doi.org\/10.1002\/cncr.32715","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]},"assertion":[{"value":"2019-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}